Bedford man begins 12 marathons of Christmas in tribute to his mum who died of cancer
The inspirational athlete describes running as his coping mechanism
William at Land s End (Image: William Goodge)
Sign up to our newsletter for daily updates and breaking newsInvalid EmailSomething went wrong, please try again later.
Sign up here!
When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. OurPrivacy Noticeexplains more about how we use your data, and your rights. You can unsubscribe at any time.
Thank you for subscribingWe have more newslettersShow meSee ourprivacy notice
Regeneron’s early stage bispecific shows promise
Bispecifics and antibody drug conjugates will challenge CAR-Ts
The potentially revolutionary nature of CAR-Ts has made them the hottest properties in haemato-oncology in recent years, but a wave of bispecific antibody therapies look set to challenge them.
Representing an evolution of the well-established monoclonal antibody platform, bispecifics can hit two or more cell surface targets. This approach could see them match the clinical performance of CAR-Ts, but with a far easier and lower cost manufacturing process, and without the risk of serious side effects including cytokine-release syndrome (CRS).
Regeneron is one many companies developing bispecifics, and on Saturday at the ASH 2018 congress in San Diego, unveiled phase 1 proof of concept data for its REGN1979 in relapsed or refractory (R/R) follicular lymphoma and diffuse large B-cell lymphoma (DLBCL), the two most common types of Non-Hodgkins Lymphoma (NHL).
The toughest question was not: what items to keep and what to let go of?
Standing in my fully filled childhood home after my father’s death in 2015, the real
kishka cruncher was: which memories to keep and which to let go of? At age 50, my bittersweet job was to partner with my big brother to pack up and chronicle our history.
The electric Hanukkah menorah, found buried in a closet, unleashed a host of hospital memories. From 1989-1995, my mother endured repeating rounds of aggressive chemotherapy.
Fighting the same Non-Hodgkins Lymphoma that took her father’s life at 60, she was diagnosed 30 years after him. Her disease flared on a hellish annual cycle: recurrence at Rosh Hashanah followed by months of chemotherapy, culminating in a ‘Prednisone Pesach’ where cleaning was a biblical reckoning.